Inhibitory effect of new quinolones on GABA(A) receptor-mediated response and its potentiation with felbinac in Xenopus oocytes injected with mouse-brain mRNA: Correlation with convulsive potency in vivo

Toxicology and Applied Pharmacology

Volumn 145, Issue 2, 1997, Pages 246-254

  Kawakami, Junichi ^a   Yamamoto, Koujirou ^a   Asanuma, Atsushi ^b   Yanagisawa, Keiji ^b   Sawada, Yasufumi ^a,c   Iga, Tatsuji ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b TSURUMI UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; CIPROFLOXACIN; FELBINAC; GLUTAMIC ACID; KAINIC ACID; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE; QUISQUALIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CONVULSION; DRUG MECHANISM; GABAERGIC TRANSMISSION; INTRACEREBRAL DRUG ADMINISTRATION; MALE; MEMBRANE CURRENT; MOUSE; NONHUMAN; OOCYTE; PREDICTION; XENOPUS;

ANIMALIA;

EID: 0031214535     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1997.8137     Document Type: Article

References (36)

1. Akahane K., Sekiguchi M., Une T., Osada Y. Structure-epileptogenicity relationship of quinolones with special reference to their interaction with γ-aminobutyric acid receptor sites. Antimicrob. Agents Chemother. 33:1989;1704-1708.
2. A. J. Neurophysiol. 66:1991;497-504.
3. Anastasio G. D., Menscer D., Little J. M. Norfloxacin and seizures. Ann. Intern. Med. 109:1988;169-170.
4. Aoshima H., Anan M., Ishii H., Iio H., Kobayashi S. Minimal model to account for the membrane conductance increase and desensitization of γ-aminobutyric acid receptors synthesized in theXenopus. Biochemistry. 26:1987;4811-4816.
5. Asanuma A., Horikoshi T., Yanagisawa K., Anzai K., Goto S. The distribution of GABA and glycine response in the mouse brain usingXenopus. Neurosci. Lett. 76:1987;87-90.
6. Chiccarelli F. S., Eisner H. J., Van Lear G. E. Disposition and metabolism of fenbufen in several laboratory animals. Arzneim. Forsch. 30:1980a;707-715.
7. Chiccarelli F. S., Eisner H. J., Van Lear G. E. Metabolic and pharmacokinetic studies with fenbufen in man. Arzneim. Forsch. 30:1980b;728-735.
8. Chishiro T., Akahori M., Kitazawa Y., Uchida K., Yamagami K., Kiuchi S., Moriguchi T., Tanaka T. Toxic side effect of new quinolone antibacterial preparations on central nervous system. Jpn. J. Acute Med. 13:1989;763-768.
9. Christ W., Lehnert T., Ulbrich B. Specific toxicologic aspects of the quinolones. Rev. Infect. Dis. 10:1988;S141-S146.
10. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
11. Davey P. G. Post-marketing surveillance of the quinolones: A view from Great Britain. Rev. Infect. Dis. 11:1989;S1402-S1407.
12. Dodd P. R., Davies L. P., Watson W. E. J., Nielsen B., Dyer J. A., Wong L. S., Johnston G. A. R. Neurochemical studies on quinolone antibiotics: Effects on glutamate, GABA and adenosine systems in mammalian CNS. Pharmacol. Toxicol. 64:1989;404-411.
13. Gundersen C. B., Miledi R., Parker I. Messenger RNA from human brain induces drug- and voltage-operated channels inXenopus. Nature. 308:1984a;421-424.
14. Gundersen C. B., Miledi R. F. R. S., Parker I. Properties of human glycine receptor expressed inXenopus. Proc. R. Soc. London B. 221:1984b;235-244.
15. Halliwell R. F., Lambert J. J., Davey P. G. Actions of quinolones and nonsteroidal antiinflammatory drugs on γ-aminobutyric acid currents of rat dorsal root ganglion neurons. Rev. Infect. Dis. 11:1989;S1398-S1399.
16. Halliwell R. F., Davey P. G., Lambert J. J. The effects of quinolones and NSAIDs upon GABA-evoked currents recorded from rat dorsal root ganglion neurones. J. Antimicrob. Chemother. 27:1991;209-218.
17. Hirai S., Tanaka K., Makino S., Narita H. Adverse drugs interactions between pyridonecarboxylic acids and nonsteroidal antiinflammatory drugs: Convulsion after oral or intracerebral administration in mice. Yakugaku Zasshi. 109:1989;119-126.
18. Hori S., Shimada J., Saito A., Matsuda M., Miyahara T. Comparison of the inhibitory effects of new quinolones on γ-aminobutyric acid receptor binding in the presence of antiinflammatory drugs. Rev. Infect. Dis. 11:1989;S1397-S1398.
19. Horikoshi T., Asanuma A., Yanagisawa K., Anzai K., Goto S. Taurine and β-alanine act on both GABA and glycine receptors inXenopus. Mol. Brain Res. 4:1988;97-105.
20. Kawahara K., Kawahara M., Goto T., Ohi Y. Penetration of sparfloxacin into the human spinal fluid: A comparative study with 5 other fluoroquinolones. Chemotherapy (Tokyo). 39:1991;149-157.
21. AXenopus. Biol. Pharm. Bull. 16:1993;726-728.
22. Montemurro D. G., Dukelow R. H. A Stereotaxic Atlas of the Diencephalon and Related Structures of the Mouse. 1992;Futura, Mount Kisco.
23. Murayama S., Suzuki T., Hara Y., Tamagawa M., Kakizaki K. Unusual central action of new quinolone group of antimicrobials. Jpn. J. Pharmacol. 43:1987;60P.
24. M. Nozaki, 1989, GABA-ergic mechanism on convulsions induced by combination with new quinolones and NSAID; true or not?, Proceedings of 16th International Congress of Chemotherapy, 1989, 407.
25. Paton J. H., Reeves D. S. Clinical features and management of adverse effects of quinolone antibacterials. Drug Safety. 6:1991;8-27.
26. Reiter C., Pfeiffer M., Hullman R. H. Brief report: Safety of ciprofloxacin based on phase IV studies ("Anwendungsbeobachtung") in the Federal Republic of Germany. Am. J. Med. 87:1989;103S-106S.
27. Schwarts M. T., Calvert J. F. Potential neurologic toxicity related to ciprofloxacin. Ann. Pharmacother. 24:1990;138-140.
28. Simon J., Guyot A. Pefloxacin: Safety in man. J. Antimicrob. Chemother. 26:1990;215-218.
29. Simpson K. J., Brodie M. J. Convulsion related to enoxacin. Lancet. II:1985;161.
30. Slavich I. L., Gleffe R. F., Haas E. J. Grand mal epileptic seizures during ciprofloxacin therapy. JAMA. 261:1989;558-559.
31. Steppuhn K. G., Turski L. Modulation of the seizure threshold for excitatory amino acids in mice by antiepileptic drugs and chemoconvulsants. J. Pharmacol. Exp. Ther. 265:1993;1063-1070.
32. Takeo G., Shibuya N., Motomura M., Kanazawa H., Shishido H. A new DNA gyrase inhibitor induces convulsions: A case report and animal experiments. Chemotherapy (Tokyo). 37:1989;1154-1159.
33. Tomaselli G. F., Marban E., Yellen G. Sodium channels from human brain RNA expressed inXenopus. J. Clin. Invest. 83:1989;1724-1732.
34. Toyoda T., Muramatsu M., Ikeda H., Okamato M., Isami Y., Ikuma T., Nakamura E., Fujii M. A case report of convulsion associated with hypoglycemia induced by enoxacin in hemodialyzed patient. J. Jpn. Soc. Dial. Ther. 24:1991;1311-1314.
35. Tsuji A., Sato H., Kume Y., Tamai I., Okezaki E., Nagata O., Kato H. Inhibitory effects of quinolone antibacterial agents on γ-aminobutyric acid binding to receptor sites on rat brain membranes. Antimicrob. Agents Chemother. 32:1988a;190-194.
36. Tsuji A., Sato H., Okezaki E., Nagata O., Kato H. Effect of the anti-inflammatory agent fenbufen on the quinolone-induced inhibition of γ-aminobutyric acid binding to rat brain membranesin vitro. Biochem. Pharmacol. 37:1988b;4408-4411.